Table 2 Baseline demographics and disease characteristics
Total, N = 20 | |
|---|---|
Sex, n (%) | |
Female | 16 (80.0) |
Male | 4 (20.0) |
Age, years, mean (SD) | 56.5 (9.43) |
BMI, kg/m2, mean (SD) | 28.5 (6.50) |
Country | |
Germany | 13 (65.0) |
USA | 7 (35.0) |
Time since PAH diagnosis at baseline, months, mean (SD) | 107.8 (90.83) |
PAH etiology, n (%) | |
Idiopathic or heritable PAH | 14 (70.0) |
PAH associated with CTD | 4 (20.0) |
PAH associated with portal hypertension | 1 (5.0) |
PAH associated with CHD | 1 (5.0) |
WHO functional class, n (%) | |
I | 1 (5.0) |
II | 13 (65.0) |
III | 6 (30.0) |
Duration on oral selexipag dose prior to first IV infusion, months, median (range) | 14.5 (2.1, 24.1) |
Ongoing PAH therapies at baseline, n (%) | |
PDE-5 inhibitor | 1 (5.0) |
sGC stimulator | 1 (5.0) |
ERA + PDE-5 inhibitor | 13 (65.0) |
ERA + sGC stimulator | 5 (25.0) |